Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
ChemoCentryx, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'ChemoCentryx, Inc. - Product Pipeline Review - 2016', provides an overview of the ChemoCentryx, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by ChemoCentryx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of ChemoCentryx, Inc. - The report provides overview of ChemoCentryx, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses ChemoCentryx, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features ChemoCentryx, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate ChemoCentryx, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for ChemoCentryx, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding ChemoCentryx, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 ChemoCentryx, Inc. Snapshot 6 ChemoCentryx, Inc. Overview 6 Key Facts 6 ChemoCentryx, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 ChemoCentryx, Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 ChemoCentryx, Inc. - Pipeline Products Glance 13 ChemoCentryx, Inc. - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 ChemoCentryx, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 ChemoCentryx, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 ChemoCentryx, Inc. - Drug Profiles 18 CCR-23G - Drug Profile 18 Product Description 18 Mechanism Of Action 18 R&D Progress 18 CCR-93G - Drug Profile 19 Product Description 19 Mechanism Of Action 19 R&D Progress 19 CCX-140 - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 CCX-168 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 CCX-354 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 CCX-507 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 CCX-6239 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 CCX-650 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 CCX-771 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 CCX-872 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 CCX-9588 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 CCX-991 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecule to Antagonize CCR1 for Undisclosed Indication - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecule to Antagonize CXCR6 for Autoimmune, Oncology and Liver Diseases - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecule to Target C5aR for Undisclosed Indication - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 vercirnon sodium - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 ChemoCentryx, Inc. - Pipeline Analysis 46 ChemoCentryx, Inc. - Pipeline Products by Target 46 ChemoCentryx, Inc. - Pipeline Products by Route of Administration 48 ChemoCentryx, Inc. - Pipeline Products by Molecule Type 49 ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action 50 ChemoCentryx, Inc. - Dormant Projects 52 ChemoCentryx, Inc. - Discontinued Pipeline Products 53 Discontinued Pipeline Product Profiles 53 CCX-832 53 vercirnon sodium 53 ChemoCentryx, Inc. - Locations And Subsidiaries 54 Head Office 54 Other Locations & Subsidiaries 54 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56
List of Tables ChemoCentryx, Inc., Key Facts 6 ChemoCentryx, Inc. - Pipeline by Indication, 2016 9 ChemoCentryx, Inc. - Pipeline by Stage of Development, 2016 11 ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2016 12 ChemoCentryx, Inc. - Phase III, 2016 13 ChemoCentryx, Inc. - Phase II, 2016 14 ChemoCentryx, Inc. - Phase I, 2016 15 ChemoCentryx, Inc. - Preclinical, 2016 16 ChemoCentryx, Inc. - Discovery, 2016 17 ChemoCentryx, Inc. - Pipeline by Target, 2016 47 ChemoCentryx, Inc. - Pipeline by Route of Administration, 2016 48 ChemoCentryx, Inc. - Pipeline by Molecule Type, 2016 49 ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action, 2016 51 ChemoCentryx, Inc. - Dormant Developmental Projects,2016 52 ChemoCentryx, Inc. - Discontinued Pipeline Products, 2016 53 ChemoCentryx, Inc., Subsidiaries 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
